Limited Competition: Continuation of the Preventing Early Renal Loss in Diabetes (PERL) Study (UC4)

Funding Opportunity RFA-DK-16-506 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to complete treatment of the participants recruited into the Preventing Early Renal Loss in Diabetes (PERL) Study and to analyze the outcomes of the trial. PERL is a randomized, double-blind trial to test whether the medication, allopurinol, can slow the progression of kidney disease in people with type 1 diabetes and early diabetic kidney disease.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding